Page 23 - Cardiff Oncology News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cardiff Oncology Announces Plans for a Randomized Trial in Metastatic Colorectal Cancer (mCRC), Durability of Responses in Ongoing Phase 1b/2 Trial in mCRC and Additional Business Updates

Next trial in RAS-mutated mCRC (ONSEMBLE) is a randomized Phase 2 trial to demonstrate onvansertib s contribution to SoC and position for a possible.

Acta oncologicaMark erlanderAmy jobeJoyce allaireVan cutsemJames levineCardiff oncology incCrc programUniversity of pittsburgh medical centerPrnewswire cardiff oncology incExchange commissionLifesci communicationsProstate cancer programEuropean society for medical oncologyDana farber cancer instituteCardiff oncology

Cardiff Oncology Announces New Preclinical and Clinical Data from Program in KRAS-mutated Metastatic Colorectal Cancer (mCRC) at the ESMO Congress 2022

Cardiff Oncology Announces New Preclinical and Clinical Data from Program in KRAS-mutated Metastatic Colorectal Cancer (mCRC) at the ESMO Congress 2022
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesFrance generalHeinz josef lenzActa oncologicaScott kopetzAmy jobeCardiff oncology incDivision of cancer medicineInova schar cancer instituteUniversity of texas md anderson cancer centerCancer centerPrnewswire cardiff oncology incDepartment of gastrointestinal medical oncologyExchange commissionPh dlifesci communicationsKansas university medical center

Cardiff Oncology (NASDAQ:CRDF) – Cardiff Oncology Announces New Preclinical and Clinical Data from Program in KRAS-mutated Metastatic Colorectal Cancer (mCRC) at the ESMO Congress 2022 - Press Release

Durable responses to treatment, with a median duration of response (mDoR) of 11.7 months, reported in Phase 1b/2 clinical trial of onvansertib plus FO

United statesFrance generalHeinz josef lenzActa oncologicaScott kopetzAmy jobeJoyce allaireJames levineDivision of cancer medicineCardiff oncology incInova schar cancer instituteUniversity of texas md anderson cancer centerCancer centerDepartment of gastrointestinal medical oncologyExchange commissionLifesci communications

Cardiff Oncology to Present at Upcoming Investor Conferences in September

/PRNewswire/ Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a.

New yorkUnited statesAmy jobeJoyce allaireJames levineCardiff oncology incLifesci communicationsPrnewswire cardiff oncology incLotte new york palace hotelBaird global healthcare conferenceAnnual global investment conferenceGlobal healthcare conferenceCardiff oncologyOncology contact

Cardiff Oncology to Host Webcast and Conference Call to Provide a Clinical and Corporate Update on September 12, 2022

/PRNewswire/ Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a.

New yorkUnited statesAmy jobeJoyce allaireJames levineCardiff oncology incLifesci communicationsPrnewswire cardiff oncology incCardiff oncologyBaird global healthcare conferenceAnnual global investment conferenceOncology contact